HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TPST
Tempest Therapeutics, Inc.
There isn't enough reported data to score TPST yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TPST Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TPST's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TPST PE Valuation
TPST has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TPST Forward outlook
There aren't enough analyst estimates for TPST to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
TPST has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus TPST down 151%.
TPST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$10.05 | +$9.84 |
| Q2 2025 | -$14.59 | +$6.21 |
| Q1 2025 | -$17.98 | +$4.38 |
| Q4 2024 | -$19.50 | +$5.33 |
| Q3 2024 | -$19.89 | +$6.50 |
| Q2 2024 | -$20.80 | +$7.93 |
| Q1 2024 | -$22.36 | +$9.62 |
| Q4 2023 | -$24.83 | +$15.34 |
TPST is still losing money, but far less than before: $10.05 per share over the past year, against $633.75 at its worst in late 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TPST Quarterly Revenue
TPST and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TPST on cash generation, producing positive trailing cash flow while its opponent burns cash.
TPST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.8M | +$5.7M |
| Q1 2026 | -$7.6M | +$438K |
| Q4 2025 | -$3.6M | +$6.6M |
| Q3 2025 | -$6.8M | +$3.4M |
| Q2 2025 | -$8.4M | -$2.7M |
| Q1 2025 | -$8M | -$682K |
| Q4 2024 | -$10.2M | -$4M |
| Q3 2024 | -$10.2M | -$3.7M |
TPST has burned cash in almost every quarter: −$21M over the past year, against −$37M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TPST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TPST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +39% | +4.3M shares |
| 1 year | +343% | +11.8M shares |
| 3 years | +1614% | +14.3M shares |
| 5 years | +15525% | +15.1M shares |
TPST has 15M diluted shares, up 343% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TPST Net Leverage
TPST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TPST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.3 | Oversold |
| Stochastic | 1.8 | Oversold |
TPST's weekly RSI is 23 (oversold) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TPST PE vs Healthcare Sector
TPST has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TPST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.60 | 37% below |
| 20 week MA | $0.82 | 54% below |
| 50 week MA | $1.65 | 77% below |
| 100 week MA | $5.33 | 93% below |
| 200 week MA | $17.0 | 98% below |
TPST is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over TPST on returns for 2026, with the stronger performance.
TPST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,339.7 | $442.7 | -67% |
| 2021 | $442.7 | $79.3 | -82% |
| 2022 | $79.3 | $16.5 | -79% |
| 2023 | $16.5 | $57.2 | +246% |
| 2024 | $57.2 | $10.9 | -81% |
| 2025 | $10.9 | $2.99 | -73% |
| 2026 YTD | $2.99 | $0.38 | -87% |
TPST's yearly returns have swung widely, from +246% in 2023 to −82% in 2021. It's down 87% so far in 2026.